OQROGet OQRO Pro
Insider trade

AbbVie (ABBV)Officer sold ~$1.35M

Perry C Siatis, Officer at AbbVie, sold ~$1.35M of AbbVie shares.

~$1.35M
Approx. value · 5,777 sh @ $233.51
18K
Holds after · shares reported
Traded
Mar 2, 2026
Filed
Mar 3, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2024CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  2. Jan 24, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  3. Apr 28, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  4. Dec 8, 2025Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $3.8K obligated to date
  5. Dec 8, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  6. Dec 18, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  7. Jan 7, 2026Company filing · Form 8-K · ResultsReported its results
  8. Jan 16, 2026FDAFDA device clearance: Natrelle 133S Tissue Expanders
  9. Jan 20, 2026Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $4K obligated to date
  10. Feb 3, 2026Federal contract · $5K obligatedDepartment of Defense awarded AbbVie: $4.6K obligated to date
  11. Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
  12. Feb 19, 2026FDAFDA drug approval: Venclexta
  13. Feb 25, 2026Insider · Their largest sale since 2023Officer sold ~$5.15M of ABBV shares in the open market
  14. Mar 2, 2026 · this disclosureInsiderOfficer sold ~$1.35M of ABBV shares in the open market

What came next

  1. Mar 2, 2026Insider · 1 personInsiders: 2 sales (~$3.0M)
  2. Mar 4, 2026InsiderOfficer sold ~$1.22M of ABBV shares in the open market
  3. Mar 5, 2026Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.4K obligated to date
  4. Mar 6, 2026FDAFDA drug approval: Skyrizi
  5. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
  6. Mar 9, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  7. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  8. Apr 3, 2026Company filing · Form 8-K · ResultsReported its results
  9. Apr 23, 2026Government · Federal Register noticeKimberly Schaff Kiehl: Final Debarment Order
  10. Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
  11. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  12. May 5, 2026CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  13. May 18, 2026FDARecall: PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only, Allergen, Inc., an AbbVie company, North Chicago, IL 60064, Product…
  14. May 19, 2026Layoff notice · 2525 Dupont Drive Irvine CA 92612Layoff notice filed in CA: 85 employees
  15. May 20, 2026FDAFDA drug approval: Venclexta
  16. May 21, 2026FDAFDA drug approval: Linzess
  17. May 27, 2026FDAFDA drug approval: Decnupaz
  18. Jun 3, 2026Government · Federal Register noticeElite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
  19. Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  20. Jun 12, 2026FDAFDA drug approval: Skyrizi
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for AbbVie

For AbbVie, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports, 130 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

Other recent filings by Perry C Siatis, EVP, GC AND SECRETARY

The full history of Perry C Siatis, EVP, GC AND SECRETARY is on the profile page.

How this filing works

Other disclosures at AbbVie

Everything OQRO holds on this company is on its ABBV page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data